Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2021-07-30 Share Issue/Capital Cha…
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
REGISTRATION STATEMENT ON FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Registration Statement on Form S-8 filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as stock option plans or restricted stock unit plans. The text includes details about the securities to be registered, the plan under which they are issued, and a reoffer prospectus for resale by selling stockholders. It is not a financial report, earnings release, management discussion, or any other report type but a registration statement related to securities issuance. According to the filing definitions, this type of document corresponds to a Share Issue/Capital Change announcement, as it relates to new shares being registered for issuance under a stock plan.
2021-07-30 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content describes the entry into a material definitive lease agreement, including terms and obligations, but does not contain financial statements or detailed financial performance data. It is not an annual or quarterly report, earnings release, or management discussion. The document is a regulatory announcement of a material contract and related financial obligation, typical of an 8-K filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-14 English
10-Q
Interim / Quarterly Report Q1 2021
2021-05-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 5, 2021, reporting the results of operations and financial condition for the quarter ended March 31, 2021. It includes a press release announcing quarterly financial results. The document explicitly states it is furnishing a press release with financial results, which is typical for an Earnings Release. The length is 3476 characters, which is short and consistent with an 8-K earnings release announcement rather than a full quarterly report. The document does not contain detailed financial statements or substantive financial data itself, but rather the announcement of the earnings results. Therefore, the appropriate classification is Earnings Release (ER).
2021-05-05 English
FORM 4 SUBMISSION
Director's Dealing
2021-04-28 English
FORM 10-K
Annual Report FY 2020
2021-03-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.